PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-7.80
Negative P/E while Drug Manufacturers - Specialty & Generic median is -0.11. Seth Klarman would scrutinize path to profitability versus peers.
15.04
P/S exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 5.41. Jim Chanos would check for potential multiple compression risks.
0.49
P/B less than half the Drug Manufacturers - Specialty & Generic median of 1.26. Joel Greenblatt would investigate if assets are truly impaired. Check ROE versus peers.
87.89
Positive FCF while Drug Manufacturers - Specialty & Generic median shows negative FCF. Peter Lynch would examine cash flow generation advantage.
74.24
P/OCF of 74.24 versus zero operating cash flow in Drug Manufacturers - Specialty & Generic. Walter Schloss would verify operational quality.
0.49
Fair value ratio less than half the Drug Manufacturers - Specialty & Generic median of 1.31. Joel Greenblatt would investigate if this discount is justified.
-3.20%
Negative earnings while Drug Manufacturers - Specialty & Generic median yield is -0.07%. Seth Klarman would investigate path to profitability.
1.14%
Positive FCF while Drug Manufacturers - Specialty & Generic median shows negative FCF. Peter Lynch would examine cash generation advantage.